Regional Epilepsy Centre, "Bianchi-Melacrino-Morelli" Great Metropolitan Hospital, Reggio Calabria, Italy.
Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Metab Brain Dis. 2023 Aug;38(6):1905-1912. doi: 10.1007/s11011-023-01216-4. Epub 2023 Apr 25.
The GLA c.337T > C (p.Phe113Leu) is a known pathogenic variant associated to late-onset Fabry disease phenotype with predominant cardiac manifestations. A founder effect was demonstrated in a large cohort in the Portuguese region of Guimarães. Herein we report an in-depth phenotype description of a cluster of five Southern Italy families.
Family pedigrees of five index males with the p.Phe113Leu variant were obtained and all at-risk relatives underwent biochemical and genetical screening test. Carriers of GLA p.Phe113Leu variant underwent subsequent multidisciplinary clinical and instrumental evaluation.
Thirty-one (16 M, 15 F) individuals with p.Phe113Leu pathogenic variant were identified. Sixteen out of 31 patients (51.6%) had cardiac manifestations. Notably, myocardial fibrosis was found in 7/8 patients, of whom 2 were under 40 years. Stroke occurred in 4 patients. White matter lesions were detected in 12/19 patients and occurred in 2/10 of subjects under 40 years. Seven females complained of acroparesthesias. Renal involvement occurred in 10 patients. Angiokeratomas were evident in 9 subjects. Eyes, ear, gastrointestinal and pulmonary involvement occurred in the minority of subjects.
This study demonstrates that a cluster of subjects with p.Phe113Leu pathogenic variant is also present in Southern Italy. Disease manifestations are frequent in both sexes and may occur early in life. Cardiac involvement represents the core manifestation, but neurological and renal involvement is also frequent, suggesting that extra-cardiac complications deserve clinical attention.
GLA c.337T > C(p.Phe113Leu)是一种已知的致病性变异,与晚发性 Fabry 疾病表型相关,主要表现为心脏表现。在葡萄牙吉马良斯地区的一个大队列中已经证明了一个起源效应。在此,我们报告了意大利南部五个家族群的深入表型描述。
获得了五个携带 p.Phe113Leu 变异的索引男性的家族系谱,并对所有高危亲属进行了生化和基因筛查测试。携带 GLA p.Phe113Leu 变异的携带者随后接受了多学科的临床和仪器评估。
确定了 31 名(16 名男性,15 名女性)携带 p.Phe113Leu 致病变异的个体。31 名患者中有 16 名(51.6%)有心脏表现。值得注意的是,7/8 名患者发现心肌纤维化,其中 2 名患者年龄小于 40 岁。4 名患者发生中风。12/19 名患者检测到脑白质病变,其中 2 名患者年龄小于 40 岁。7 名女性抱怨四肢感觉异常。10 名患者存在肾脏受累。9 名患者有血管角皮瘤。眼部、耳部、胃肠道和肺部受累在少数患者中发生。
本研究表明,p.Phe113Leu 致病变异的一群患者也存在于意大利南部。两性均可频繁发病,且可能在生命早期发生。心脏受累是核心表现,但神经和肾脏受累也很常见,这表明心脏外并发症值得临床关注。